Ideaya Biosciences, Servier announce exclusive darovasertib license agreement

Servier and Ideaya Biosciences (IDYA) announced an exclusive license agreement to bring darovasertib to patients worldwide. Under the agreement, Servier obtains the regulatory and commercial rights for darovasertib in all territories outside the United States. Ideaya retains its rights for darovasertib in the United States. Darovasertib, a potent and selective protein kinase C inhibitor, is being developed to broadly address primary and metastatic uveal melanoma. Under the terms of the agreement, Ideaya will receive an upfront payment of $210M, and be eligible for up to $100M in regulatory approval-based milestone payments and up to $220M in commercial milestone payments, as well as double-digit royalties on net sales in all territories outside of the United States. Servier will be responsible for the regulatory and commercial activities for darovasertib in all territories outside the United States. Ideaya and Servier will collaborate on the development of darovasertib and share the associated costs.